BioVeda China Fund (BVCF) is a Chinese investment firm based in Beijing, China.
History
BVCF was founded by Zhi Yang in 2005 as China's first US dollar-based fund focused on life sciences and healthcare.[1]
COVID-19
In July 2019, BVCF participated in BioNTech's $325 million Series B investment round.[2][3]
Portfolio
Companies in BVCF's investment portfolio include:[4]
- 111
- AcuVu
- Allgens
- Biocytogen
- BioNTech
- Boan Biotech
- CARsgen Therapeutics
- Cathay Industrial Biotech
- Cellenkos
- Cingular Biotech
- CITIC Pharmaceuticals
- Clarus Therapeutics
- CurePharma
- DiaCarta
- Drug Farm
- DTRM Biopharma
- Ealong Biotech
- Extong Technology
- GenEros Biopharma
- Genova
- Jiyuan Medical
- Kunshan RiboQuark Pharmaceutical Technology
- MicuRx Pharmaceuticals
- Napo Pharmaceuticals
- Novast Laboratories
- Oculis
- Sinobiopharma
- Stealth BioTherapeutics
- VivaLNK
- Wekair
- Yashentech
- Yidu Healthcare
External links
Yang, Z. About. BioVeda China Fund (BVCF). Retrieved May 24, 2022, from https://web.archive.org/web/20220524221558/https://bvcf.com/about.asp?nav=2 ↩︎
BioNTech - Funding, Financials, Valuation & Investors. Crunchbase. Retrieved December 28, 2022, from https://www.crunchbase.com/organization/biontech-ag/company_financials/investors ↩︎
Boehler, M., Schweitzer, G., & May, S. (2019, July 9). BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline. BioNTech. https://web.archive.org/web/20221229025707/https://investors.biontech.de/news-releases/news-release-details/biontech-raises-usd-325-million-upsized-series-b-financing/ ↩︎
Portfolio. BioVeda China Fund (BVCF). Retrieved December 29, 2022, from http://archive.today/2022.12.29-070051/https://www.bvcf.com/portfolio.asp?nav=4 ↩︎
